Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

<b>Background/Objectives</b>: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. <b>Methods</b>: A multicentric study evaluated tralokinumab's efficacy over 52 weeks in 416 severe AD patients. EASI (Eczema Area and Severity Index), P-NRS (Pruritus Numerical Rating Scale), DLQI (Dermatology Life Quality Index), and ADCT (Atopic Dermatitis Control Tool) were recorded up to 52 weeks of treatment. <b>Results</b>: The EASI, P-NRS, DLQI, and ADCT trends across phenotypes showed significant improvement in all phenotype subgroups. By week 16, classical and generalized lichenoid phenotypes showed the highest EASI improvements compared to the generalized inflammatory (75.0 vs. 45.5 [<i>p</i> < 0.001] and 79.3 vs. 45.5 [<i>p</i> < 0.001]), with most achieving EASI-75 (<i>p</i> < 0.001, χ<sup>2</sup> = 25.96). By week 24, generalized lichenoid reached 100% EASI improvement, significantly outperforming other phenotypes. The highest EASI-75 rates were seen in classical, generalized lichenoid, and portrait/head and neck phenotypes (<i>p</i> = 0.016, χ<sup>2</sup> = 13.85). No significant differences were observed at weeks 32, 40, or 52. <b>Conclusions</b>: Our results suggest that tralokinumab's durability and tolerability are consistent across the various phenotypes. The classical and generalized lichenoid were the fastest phenotypes to improve. However, given the uneven distribution of phenotypes and the gradual reduction in patient numbers over time, larger prospective studies are essential to confirm the observed trends.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-03-18
DOI
https://doi.org/10.3390/jcm14062077
Citations
3
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
6.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

Martina Maurelli, Vincenzo Panasiti, Angelo Valerio Marzano, Simone Ribero et al.
3 citations
Journal of Clinical Medicine
Dermatology and Skin Diseases
6.01
article

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes

Martina Maurelli, Vincenzo Panasiti, Angelo Valerio Marzano, Simone Ribero, Giovanni D’Agostino, Maddalena Napolitano, Giampiero Girolomoni, Mariateresa Rossi, Emanuele Cozzani, Tommaso Bianchelli, M. Dall’Olio, Anna Campanati, Luca Stingeni, Ilaria Trave, Francesca Caroppo, Mario Bruno Guanti, Anna Belloni Fortina, Paolo Calzari, Michela Ortoncelli, Elena Pezzolo, Cataldo Patruno, Eustachio Nettis, Silvia Mariel Ferrucci, Rosa Coppola, Francesca Barei, Katharina Hansel, Francesco Pugliese, Francesca di Vico, Laura Grigolato
article en
3 citations

Abstract

<b>Background/Objectives</b>: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. <b>Methods</b>: A multicentric study evaluated tralokinumab's efficacy over 52 weeks in 416 severe AD patients. EASI (Eczema Area and Severity Index), P-NRS (Pruritus Numerical Rating Scale), DLQI (Dermatology Life Quality Index), and ADCT (Atopic Dermatitis Control Tool) were recorded up to 52 weeks of treatment. <b>Results</b>: The EASI, P-NRS, DLQI, and ADCT trends across phenotypes showed significant improvement in all phenotype subgroups. By week 16, classical and generalized lichenoid phenotypes showed the highest EASI improvements compared to the generalized inflammatory (75.0 vs. 45.5 [<i>p</i> < 0.001] and 79.3 vs. 45.5 [<i>p</i> < 0.001]), with most achieving EASI-75 (<i>p</i> < 0.001, χ<sup>2</sup> = 25.96). By week 24, generalized lichenoid reached 100% EASI improvement, significantly outperforming other phenotypes. The highest EASI-75 rates were seen in classical, generalized lichenoid, and portrait/head and neck phenotypes (<i>p</i> = 0.016, χ<sup>2</sup> = 13.85). No significant differences were observed at weeks 32, 40, or 52. <b>Conclusions</b>: Our results suggest that tralokinumab's durability and tolerability are consistent across the various phenotypes. The classical and generalized lichenoid were the fastest phenotypes to improve. However, given the uneven distribution of phenotypes and the gradual reduction in patient numbers over time, larger prospective studies are essential to confirm the observed trends.

Journal of Clinical MedicineVol. 14(6)
University of Verona (IT), Marche Polytechnic University (IT), University of Padua (IT), Università Campus Bio-Medico (IT), University of Milan (IT), University of Perugia (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Magna Graecia University (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Campus Bio Medico University Hospital (IT), Ospedale Policlinico San Martino (IT), Ospedale San Bortolo (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Istituto Nazionale di Riposo e Cura per Anziani (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Genoa (IT)
Ministero della Salute
Responsible consumption and production
Openalex Percentile: Top 5%
Dermatology and Skin Diseases
6.01
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.